Endogenous Competition of circ_001024 for miR-145-3p in RCC

Overview

This study identifies Circ_001024 as significantly upregulated in renal cell carcinoma (RCC) tissues, correlating with disease advancement. It explores the role of Circ_001024 in RCC progression and its potential as a therapeutic target.

Background

Renal cell carcinoma (RCC) is a prevalent malignancy with a high risk of recurrence and metastasis post-surgery. Understanding the molecular mechanisms underlying RCC is crucial for developing personalized treatment strategies. Circular RNAs (circRNAs) like Circ_001024 may play a significant role in RCC pathogenesis by interacting with microRNAs.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Circ_001024 is significantly upregulated in RCC tissues.
• Its expression correlates with disease advancement in RCC patients.
• CircRNAs can function as microRNA sponges, influencing cancer progression.
• Understanding circRNA interactions may provide insights into RCC treatment strategies.
• Further investigation is needed to explore the regulatory network of circRNAs in RCC.

Clinical Implications

The identification of Circ_001024 as a potential biomarker for RCC progression may aid in early diagnosis and personalized treatment approaches. Targeting circRNA interactions could represent a novel therapeutic strategy in managing RCC.

Conclusion

Circ_001024's role in RCC highlights the importance of circRNAs in cancer biology and their potential as therapeutic targets. Further research is essential to fully elucidate their mechanisms in RCC.

References

1. Gastric Cancer, 2019 -- CircDUSP16 facilitates gastric cancer progression and invasion through miR-145-5p sponging
2. Journal of Gastroenterology, 2025 -- The Critical Function of SFRP2 in Enhancing Glycolysis and Disease Advancement in High-Risk Colorectal Cancer Patients Based on a Glycometabolism Prognostic Model
3. Archives of Toxicology, 2021 -- Influence of microRNAs on the response to cadmium chloride in pancreatic ductal adenocarcinoma
4. The Journal of Clinical Endocrinology & Metabolism -- Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia
5. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2024
6. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
7. Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition
8. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
9. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial - PubMed
10. Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition - The ASCO Post